Targetome Overview
- Founded
- 2010
- Status
- Out of Business
- Latest Deal Type
- Out of Business
Targetome General Information
Description
Developer of affinity-based targeted therapies intended to be used for the diagnosis of pancreatic cancer. The company's therapies works with the help of a bio marker discovery platform, enabling healthcare professionals to receive advanced treatment procedures of pancreatic cancer and liver metastases.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- GIGA EE1 Tower
- Avenue Hippocrate 5
- 4000 Liège
- Belgium
+32 04 000 00 00
Targetome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Apr-2018 | 00.000 | Completed | Out of Business | ||
| 4. Grant | 29-Feb-2016 | 00000 | 00.000 | Completed | Generating Revenue | |
| 3. Early Stage VC | 09-Oct-2015 | 00000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 2. Early Stage VC | 26-Jul-2013 | $1.08M | $1.08M | 00.000 | Completed | Generating Revenue |
| 1. Accelerator/Incubator | 01-Sep-2011 | Completed | Generating Revenue |
Targetome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class G | 0,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | ||
| Class F | 000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | ||
| Class C | 000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
| Preference | 2,252 | $336.88 | $336.88 | 1x | $336.88 | 40.02% | ||
| Preference | 500 | $336.88 | $336.88 | 1x | $336.88 | 8.89% |